Reported Q: Q4 2024 Rev YoY: N/A EPS YoY: -98.4% Move: +0.79%
Lin BioScience Inc
6696.TWO
TWD384.50 0.79%
Exchange TWO Sector Healthcare Industry Biotechnology
Q4 2024
Published: Dec 31, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 6696.TWO

Reported

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

N/A

YoY: N/A

EPS

-5.06

YoY: -98.4%

Market Move

+0.79%

Previous quarter: Q2 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • EPS of $-5.06 decreased by 98.4% from previous year
  • Net income of -397.44M
  • "N/A" - N/A
6696.TWO
Company 6696.TWO

Swipe to view all report sections

Executive Summary

Lin BioScience reported a substantial quarterly operating loss in QQ4 2024, with no revenue disclosed in the period. The company posted an operating loss of 822,334,000 TWD and an EBITDA of -818,918,000 TWD, driven by an R&D burden of 570,396,000 TWD and SG&A of 251,936,000 TWD. Net income totaled -397,436,000 TWD, corresponding to an EPS of -5.06. Given the lack of revenue visibility in the quarter and the high R&D intensity, the result underscores the ongoing clinical development focus and the burn required to advance the pipeline.

Key Performance Indicators

Operating Income
Decreasing
-822.33M
QoQ: -29.43% | YoY: -156.43%
Net Income
Decreasing
-397.44M
QoQ: -14.59% | YoY: -106.55%
EPS
Decreasing
-5.06
QoQ: -14.48% | YoY: -98.43%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 0.00 -3.84 +0.0% View
Q1 2025 0.00 -3.84 +0.0% View
Q4 2024 0.00 -5.06 +0.0% View
Q2 2024 0.00 -2.21 +0.0% View
Q1 2024 0.00 -2.21 +0.0% View